{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:32:22Z","timestamp":1768012342515,"version":"3.49.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4,1]]},"DOI":"10.1093\/jac\/dkl552","type":"journal-article","created":{"date-parts":[[2007,2,17]],"date-time":"2007-02-17T01:18:27Z","timestamp":1171675107000},"page":"690-697","source":"Crossref","is-referenced-by-count":42,"title":["Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis"],"prefix":"10.1093","volume":"59","author":[{"given":"Esteban","family":"Ribera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Azuaje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa M.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adria","family":"Curran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Feijoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonor","family":"Pou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paquita","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Antonia","family":"Sambeat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Lluis","family":"Lopez-Colomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicen\u00e7","family":"Falc\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imma","family":"Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Pahissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,2,16]]},"reference":[{"key":"key\n\t\t\t\t20171012155211_DKL552C1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.med.55.091902.103753","article-title":"Clinical management of tuberculosis in the context of HIV infection","volume":"55","author":"De Jong","year":"2004","journal-title":"Annu Rev Med"},{"key":"key\n\t\t\t\t20171012155211_DKL552C2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1086\/424676","article-title":"Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy","volume":"190","author":"Dheda","year":"2004","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171012155211_DKL552C3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00002030-199903110-00001","article-title":"The treatment of tuberculosis in HIV-infected persons","volume":"13","author":"Pozniak","year":"1999","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171012155211_DKL552C4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","article-title":"Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis","volume":"41","author":"Lopez-Cortes","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20171012155211_DKL552C5","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/01.aids.0000183630.27665.30","article-title":"Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin","volume":"19","author":"Manosuthi","year":"2005","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171012155211_DKL552C6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00042560-200112150-00007","article-title":"Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis","volume":"28","author":"Ribera","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171012155211_DKL552C7","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/00002030-200106150-00018","article-title":"Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin","volume":"15","author":"Moreno","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171012155211_DKL552C8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1086\/380794","article-title":"Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients","volume":"38","author":"Justesen","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012155211_DKL552C9","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","article-title":"Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers","volume":"48","author":"La Porte","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012155211_DKL552C10","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1128\/AAC.00461-06","article-title":"Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers","volume":"50","author":"Burger","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012155211_DKL552C11","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1086\/313548","article-title":"Ritonavir enables combined therapy with rifampin and saquinavir","volume":"29","author":"Veldkamp","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012155211_DKL552C12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jac\/dki320","article-title":"Once-daily antiretroviral therapy: Spanish Consensus Statement","volume":"56","author":"Pulido","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171012155211_DKL552C13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00126334-200304010-00005","article-title":"Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects","volume":"32","author":"Cardiello","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171012155211_DKL552C14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/135965350400900202","article-title":"Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study)","volume":"9","author":"Lamotte","year":"2004","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20171012155211_DKL552C15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00126334-200302010-00019","article-title":"Once-daily saquinavir-sgc plus low-dose ritonavir (1200\/100\u00a0mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy","volume":"32","author":"Lopez-Cortes","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171012155211_DKL552C16","doi-asserted-by":"crossref","first-page":"F103","DOI":"10.1097\/00002030-200006160-00003","article-title":"Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study","volume":"14","author":"Van Heeswijk","year":"2000","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171012155211_DKL552C17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.qai.0000182629.74336.4d","article-title":"Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study)","volume":"40","author":"Ribera","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20171012155211_DKL552C18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00007691-199712000-00011","article-title":"Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies","volume":"19","author":"Le Guellec","year":"1997","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20171012155211_DKL552C19","first-page":"1558","article-title":"Determination of isoniazid in plasma by liquid chromatography","volume":"52","author":"Gupta","year":"1988","journal-title":"J Chromatogr"},{"key":"key\n\t\t\t\t20171012155211_DKL552C20","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1128\/AAC.48.11.4256-4262.2004","article-title":"Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults","volume":"48","author":"Ribera","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012155211_DKL552C21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/jac\/dkh415","article-title":"Pharmacokinetic study of saquinavir hard gel caps\/ritonavir in HIV-1-infected patients: 1600\/100\u00a0mg once-daily compared with 2000\/100\u00a0mg once-daily and 1000\/100\u00a0mg twice-daily","volume":"54","author":"Autar","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171012155211_DKL552C22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/135965350400900315","article-title":"Pharmacokinetics of once-daily saquinavir\/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen","volume":"9","author":"Boffito","year":"2004","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20171012155211_DKL552C23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1177\/135965350501000703","article-title":"Saquinavir 500\u00a0mg film-coated tablets demonstrate bioequivalence to saquinavir 200\u00a0mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers","volume":"10","author":"Bittner","year":"2005","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20171012155211_DKL552C24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1468-1293.2003.00143.x","article-title":"Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers","volume":"4","author":"Kurowski","year":"2003","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20171012155211_DKL552C25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1468-1293.2002.00090.x","article-title":"The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects","volume":"3","author":"Kilby","year":"2002","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20171012155211_DKL552C26","article-title":"Unexpected hepatotoxicity observed in a healthy volunteer study on the effects of multiple dose rifampicin on the steady-state pharmacokinetics of ritonavir-boosted saquinavir and vice versa","volume-title":"Abstracts of the Sixth International Workshop on Clinical Pharmacology of HIV Therapy","author":"Grange","year":"2005"},{"key":"key\n\t\t\t\t20171012155211_DKL552C27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/499244","article-title":"Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection","volume":"42","author":"Ijaz","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012155211_DKL552C28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/135965350400900606","article-title":"The use of saquinavir\/ritonavir 1000\/100\u00a0mg twice daily in patients with tuberculosis receiving rifampin","volume":"9","author":"Losso","year":"2004","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20171012155211_DKL552C29","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis","volume":"62","author":"Peloquin","year":"2002","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171012155211_DKL552C30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1086\/514513","article-title":"Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea","volume":"25","author":"Choudhri","year":"1997","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012155211_DKL552C31","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1128\/AAC.48.11.4473-4475.2004","article-title":"Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease","volume":"48","author":"Gurumurthy","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012155211_DKL552C32","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1378\/chest.120.5.1520","article-title":"Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy","volume":"120","author":"Mehta","year":"2001","journal-title":"Chest"},{"key":"key\n\t\t\t\t20171012155211_DKL552C33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/ajrccm.159.3.9804147","article-title":"Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients","volume":"159","author":"Murray","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171012155211_DKL552C34","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1164\/ajrccm.154.4.8887603","article-title":"Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection","volume":"154","author":"Chaisson","year":"1996","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/59\/4\/690\/1971307\/dkl552.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T00:43:39Z","timestamp":1707612219000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/59\/4\/690\/676408\/Pharmacokinetic-interaction-between-rifampicin-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,16]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2007,2,16]]},"published-print":{"date-parts":[[2007,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkl552","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,4]]},"published":{"date-parts":[[2007,2,16]]}}}